---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-009785"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:31:19.428691+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M

## Summary
- Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).
- Q4 net income $7.2M vs $0.1M a year ago; full-year net income $8.6M vs net loss $4.9M in 2023.
- Adjusted EBITDA $8.5M in 2024; operating cash flow $12.1M; cash $44.7M with no debt.
- G&A expense dropped $6.6M for the year due to $3.5M royalty reversal and $1.3M legal settlement recovery.
- FDA granted Orphan Drug and Rare Pediatric Disease Designations for NR; Niagen Plus now at 475+ clinics.

## SEC filing metadata
- accession: 0001628280-25-009785
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828025009785/0001628280-25-009785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828025009785/cdxc-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-009785
- JSON: https://secwatch.observer/filing/0001628280-25-009785.json
- Plain text: https://secwatch.observer/filing/0001628280-25-009785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.